ATE136909T1 - Igg3-antikörper mit verkürzter hinge-region und einem komplementaktivierungstest - Google Patents

Igg3-antikörper mit verkürzter hinge-region und einem komplementaktivierungstest

Info

Publication number
ATE136909T1
ATE136909T1 AT90910699T AT90910699T ATE136909T1 AT E136909 T1 ATE136909 T1 AT E136909T1 AT 90910699 T AT90910699 T AT 90910699T AT 90910699 T AT90910699 T AT 90910699T AT E136909 T1 ATE136909 T1 AT E136909T1
Authority
AT
Austria
Prior art keywords
pct
complement activation
antibody
hinge region
complement
Prior art date
Application number
AT90910699T
Other languages
English (en)
Inventor
Terje Michaelsen
Inger Sandlie
Original Assignee
Dynal As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynal As filed Critical Dynal As
Application granted granted Critical
Publication of ATE136909T1 publication Critical patent/ATE136909T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT90910699T 1989-07-18 1990-07-17 Igg3-antikörper mit verkürzter hinge-region und einem komplementaktivierungstest ATE136909T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898916400A GB8916400D0 (en) 1989-07-18 1989-07-18 Modified igg3

Publications (1)

Publication Number Publication Date
ATE136909T1 true ATE136909T1 (de) 1996-05-15

Family

ID=10660201

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90910699T ATE136909T1 (de) 1989-07-18 1990-07-17 Igg3-antikörper mit verkürzter hinge-region und einem komplementaktivierungstest

Country Status (8)

Country Link
US (1) US5348876A (de)
EP (1) EP0483194B1 (de)
JP (1) JPH05500303A (de)
AT (1) ATE136909T1 (de)
DE (1) DE69026615T2 (de)
DK (1) DK0483194T3 (de)
GB (1) GB8916400D0 (de)
WO (1) WO1991001335A1 (de)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6893636B2 (en) * 1997-02-20 2005-05-17 Biogen Idec Ma Inc. Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US7033589B1 (en) * 1997-02-20 2006-04-25 Biogen Idec Ma Inc. γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
SI1068241T1 (sl) 1998-04-02 2007-12-31 Genentech Inc Protitelesne variante in njihovi fragmenti
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
MXPA01007170A (es) * 1999-01-15 2002-07-30 Genentech Inc Variantes de polipeptidos con funcion efectora alterada.
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6193892B1 (en) 1999-03-03 2001-02-27 Promega Corporation Magnetic separation assembly and method
JP2003531149A (ja) * 2000-04-13 2003-10-21 ザ・ロツクフエラー・ユニバーシテイ 抗体由来の免疫応答の増強
FR2836146B1 (fr) * 2002-02-15 2005-01-07 Urrma R & D IMMUNOGLOBULINE IgG3 MARQUEUR DE PROTECTION CONTRE LES MALADIES VIRALES INFECTIEUSES ET SES UTILISATIONS
US8946387B2 (en) * 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8530627B2 (en) * 2002-08-14 2013-09-10 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8193318B2 (en) * 2002-08-14 2012-06-05 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8044180B2 (en) * 2002-08-14 2011-10-25 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8187593B2 (en) * 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
JP4033390B2 (ja) * 2002-10-30 2008-01-16 独立行政法人科学技術振興機構 不死化ナチュラルキラー細胞株
MXPA05004677A (es) 2002-10-31 2005-11-17 Genentech Inc Metodos y composiciones para aumentar la produccion de anticuerpos.
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP1641826A2 (de) * 2003-06-27 2006-04-05 Biogen Idec MA Inc. Verwendung der hydrophoben-interaktions-chromatographie oder hinge-regionen modifikationen zur herstellung homogener antikörperlösung
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
AU2004273791A1 (en) * 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
BRPI0418286A (pt) * 2003-12-30 2007-05-02 Merck Patent Gmbh proteìnas de fusão de il-7
US8309318B2 (en) * 2004-02-10 2012-11-13 Brendan Bioscience, Llc Detection of antigen specific immunocomplexes
WO2005078442A1 (en) * 2004-02-10 2005-08-25 Dantini Daniel C Comprehensive food allergy test
EP1761563A4 (de) 2004-05-10 2008-05-14 Macrogenics Inc HUMANISIERTE FC gamma SPEZIFISCHE ANTIKÖRPER UND VERFAHREN ZU DEREN ANWENDUNG
EP1776384B1 (de) 2004-08-04 2013-06-05 Mentrik Biotech, LLC Variante fc-regionen
EP1778728A2 (de) * 2004-08-19 2007-05-02 Genentech, Inc. Polypeptidvarianten mit veränderten effektorfunktionen
JP2008511337A (ja) * 2004-09-02 2008-04-17 ジェネンテック・インコーポレーテッド ヘテロ多量体分子
CA2587766A1 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
EP1674479A1 (de) * 2004-12-22 2006-06-28 Memorial Sloan-Kettering Cancer Center Modulierung von Fc-gamma-Rezeptoren zur Optimierung einer Immunotherapie
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
ES2707152T3 (es) * 2005-04-15 2019-04-02 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
US9963510B2 (en) * 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) * 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
EP2573114B1 (de) 2005-08-10 2016-03-30 MacroGenics, Inc. Identifizierung und Herstellung von Antikörpern mit abweichenden Fc-Regionen und Anwendungsverfahren dafür
JP2009529331A (ja) * 2006-03-10 2009-08-20 マクロジェニクス，インコーポレーテッド 変異型重鎖を有する抗体の同定および工学的改変ならびにその使用方法
GB2436616A (en) * 2006-03-29 2007-10-03 Inverness Medical Switzerland Assay device and method
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
DK2009101T3 (en) 2006-03-31 2018-01-15 Chugai Pharmaceutical Co Ltd Antibody modification method for purification of a bispecific antibody
WO2008105886A2 (en) 2006-05-26 2008-09-04 Macrogenics, Inc. HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
WO2008019199A2 (en) 2006-06-26 2008-02-14 Macrogenics, Inc. FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
CA2656224C (en) * 2006-06-26 2018-01-09 Macrogenics, Inc. Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof
WO2008007159A1 (en) * 2006-07-14 2008-01-17 Eötvös Lorand University Measurement of complement activation products on antigen arrays
US20080112961A1 (en) * 2006-10-09 2008-05-15 Macrogenics, Inc. Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
US8652466B2 (en) * 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
SI2202245T1 (sl) 2007-09-26 2016-10-28 Chugai Seiyaku Kabushiki Kaisha Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR
MY163473A (en) 2007-09-26 2017-09-15 Chugai Pharmaceutical Co Ltd Modified antibody constant region
WO2009117030A2 (en) * 2007-12-19 2009-09-24 Macrogenics, Inc. Improved compositions for the prevention and treatment of smallpox
KR101614494B1 (ko) 2008-04-02 2016-04-22 마크로제닉스, 인크. Ｂｃｒ-복합체-특이적 항체 및 그것의 사용 방법
EP2247304B1 (de) 2008-04-02 2016-05-25 MacroGenics, Inc. Her2/neu-spezifische antikörper und methoden zu ihrer verwendung
EP2282770B1 (de) * 2008-06-04 2018-03-07 MacroGenics, Inc. Antikörper mit veränderter bindung an fcrn und verwendungsverfahren dafür
JP5787446B2 (ja) 2009-03-19 2015-09-30 中外製薬株式会社 抗体定常領域改変体
WO2010107110A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
US10150808B2 (en) * 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
ES2672121T3 (es) 2009-10-07 2018-06-12 Macrogenics, Inc. Polipéptidos que contienen región Fc que presentan una función efectora mejorada debido a alteraciones del grado de fucosilación, y métodos para su uso
EP2543730B1 (de) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Variante einer konstanten antikörperregion
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
LT2542256T (lt) 2010-03-04 2019-10-25 Macrogenics Inc Su b7-h3 reaguojantys antikūnai, jų imunologiškai aktyvūs fragmentai ir jų naudojimas
SG187682A1 (en) 2010-08-02 2013-03-28 Macrogenics Inc Covalent diabodies and uses thereof
SG193554A1 (en) 2011-03-29 2013-11-29 Roche Glycart Ag Antibody fc variants
UA111612C2 (uk) 2011-05-21 2016-05-25 Макродженікс, Інк. Домени, які зв'язуються з деімунізованою сироваткою, і їхнє застосування для збільшення часу напівжиття в сироватці
CN104428315B (zh) 2012-07-13 2017-09-29 罗氏格黎卡特股份公司 双特异性抗‑vegf/抗‑ang‑2抗体及其在治疗眼血管疾病中的应用
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
CN105189561B (zh) 2013-03-14 2021-02-26 宏观基因有限公司 与表达激活受体的免疫效应细胞和由被病毒感染的细胞表达的抗原具有免疫反应性的双特异性分子及其用途
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
EP2839842A1 (de) 2013-08-23 2015-02-25 MacroGenics, Inc. Bispezifische monovalente Diabodies mit Fähigkeit zur Bindung von CD123 und CD3 und Verwendungen davon
EP2840091A1 (de) 2013-08-23 2015-02-25 MacroGenics, Inc. Bispezifische Diabodies, die gpA33 und CD3 binden können und Anwendungen dieser
BR112016006197B1 (pt) 2013-09-27 2023-04-11 Chugai Seiyaku Kabushiki Kaisha Método para produzir um anticorpo biespecífico de polipeptídeos
MX2017004076A (es) 2014-09-29 2017-07-04 Univ Duke Moleculas biespecificas que comprenden un brazo orientado a la envoltura vih-1.
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
EP3398965A4 (de) 2015-12-28 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Verfahren zur förderung der effizienz der reinigung von polypeptid mit fc-region
MX2018012433A (es) 2016-04-15 2019-03-01 Macrogenics Inc Moleculas de union b7-h3 novedosas, conjugados anticuerpo-farmaco de los mismos y metodos de uso de los mismos.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2840847A1 (de) * 1978-09-20 1980-04-03 Behringwerke Ag Verfahren zum nachweis und zur bestimmung komplementbindender antikoerper
JP3101690B2 (ja) * 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
FR2609398A1 (fr) * 1988-04-19 1988-07-15 Zagyansky Yuly Structure de l'igg plus antigene et complement, ses mecanismes et les consequences importantes
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
WO1989007142A1 (en) * 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies

Also Published As

Publication number Publication date
JPH05500303A (ja) 1993-01-28
DK0483194T3 (da) 1996-05-13
DE69026615D1 (de) 1996-05-23
EP0483194B1 (de) 1996-04-17
US5348876A (en) 1994-09-20
EP0483194A1 (de) 1992-05-06
DE69026615T2 (de) 1996-09-26
GB8916400D0 (en) 1989-09-06
WO1991001335A1 (en) 1991-02-07

Similar Documents

Publication Publication Date Title
ATE136909T1 (de) Igg3-antikörper mit verkürzter hinge-region und einem komplementaktivierungstest
ES2009939A6 (es) Un inmunoensayo para la deteccion simultanea de antigenos yno anticuerpos en una muestra a ensayar de un fluido fisiologico.
ES2119369T3 (es) Dispositivo sensor para un ensayo sandwich.
KR940005957A (ko) 항-글리코헤모글로빈 단일클론 항체 및 글리코헤모글로빈의 측정 방법
ES512498A0 (es) "metodo y su correspondiente aparato para el ensayo de anticuerpos con respecto a antigenos solubles".
DE3883073D1 (de) Einschritt-immuntest zur bestimmung von antigen-spezifischen antikoerpern aus einer der immunglobulin-klassen a, m, d oder e und dazu geeignetes mittel.
DE69106002D1 (de) Testverfahren und reagenziensatz dafür.
DE3779704D1 (de) Verfahren und testkit zur bestimmung freier wirkstoffe in biologischen fluessigkeiten.
DE69124511T2 (de) Verfahren für den nachweis und/oder die bestimmung von hormonen
DE59509344D1 (de) Antikörperklassenspezifisches entstörungsreagenz
BR9507389A (pt) Método para detectar a presença de uma espécie mycobacterium e um kit e anticorpos para uso no mesmo
DE3686717D1 (de) Immuntestverfahren.
Reid et al. Biological and chemical differences among proteins having reaginic activity
ATE188551T1 (de) Feststellung von antikörperproduktion
ATA261687A (de) Laktoferrin enthaltendes inkubationsmedium für festphasen-immunometrische verfahren und seine verwendung
DK608789A (da) Cea-immunanalyse uden falske positive foraarsaget af humant anti-museantistof
ATE286596T1 (de) Chemische modifikation von antikörpern und antigenen
ATE249627T1 (de) Vorrichtung und test zur bestimmung eines antigens oder eines antikörpers in einer testprobe
DE3863270D1 (de) Immuntest.
ES8608321A1 (es) Hibridomas productores de anticuerpos monoclonales especifi-cos para la inmunoglobulina e (ige)humana del mieloma ns

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee